Coeliac disease (CD) also known as gluten-sensitive enteropathy or non-tropical sprue is relatively uncommon condition. The dietary presence of an alcohol-soluble subfraction of gluten called gliadin in immunologically susceptible hosts will lead to small intestinal mucosal inflammation and subsequent mucosal villous atrophy which results in nutrient and vitamin malabsorption. Diagnosis of CD is confirmed by (1) histological demonstration of villous atrophy, although increasingly lesser degrees of histological changes are recognized as being compatible with CD; and (2) clinical improvement after excluding gluten. To date the most commonly accepted serological tests for the screening of CD are indirect immunofluorescence and enzyme-linked immunosorbent assay (ELISA) which reveal antiendomysial antibodies and anti-gliadin antibodies respectively. Tissue transglutaminase (tTG) is the antigen for antiendomysial antibodies, whose power in screening for CD has been recognized recently. Recombinant tTG proved to be a major target of antibodies in CD. A number of hepatobiliary tract and pancreatic disorders have been described in patients with CD. Some of these disorders have shared immunological or genetic factors, including chronic hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis. Therefore CD should be considered when evaluating a child with elevated levels of serum transaminases and in cases of cryptogenic liver disease. The present study included 40 children with chronic liver disease. They were divided into 2 groups. Group I included 26 patients (65%) with Autoimmune Hepatitis (AIH) and group II included 14 patients (35%) with cryptogenic liver disease.